Kolli Priyanka, Kelley Grace, Rosales Marianela, Faden Justin, Serdenes Ryan
Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Department of Psychiatry and Human Behavior, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Pharmgenomics Pers Med. 2023 Dec 21;16:1097-1108. doi: 10.2147/PGPM.S391401. eCollection 2023.
Olanzapine is one of the most widely used antipsychotics since its initial approval by the US Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study. Despite being utilized in clinical psychiatry for decades, there remain questions regarding the variety of available formulations, the utility of therapeutic drug monitoring, altered kinetic properties in special populations/medical illnesses, the use of high-dose olanzapine, and drug interactions, among many others. We performed a narrative literature review of olanzapine pharmacokinetics in June 2023 using the US National Library of Medicine's PubMed.gov resource (https://www.ncbi.nlm.nih.gov/pubmed) and Google Scholar. Herein, we review clinically relevant aspects of olanzapine pharmacokinetic data while highlighting knowledge gaps and potential areas of future study.
自1996年被美国食品药品监督管理局首次批准以来,奥氮平是使用最广泛的抗精神病药物之一,并已进行了广泛的药代动力学研究。尽管在临床精神病学中使用了数十年,但关于现有剂型的种类、治疗药物监测的效用、特殊人群/疾病中改变的动力学特性、高剂量奥氮平的使用以及药物相互作用等诸多问题仍然存在。我们于2023年6月使用美国国立医学图书馆的PubMed.gov资源(https://www.ncbi.nlm.nih.gov/pubmed)和谷歌学术对奥氮平的药代动力学进行了叙述性文献综述。在此,我们回顾奥氮平药代动力学数据的临床相关方面,同时突出知识空白和未来研究的潜在领域。